Cargando…

Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials

BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Garibaldi, Matteo, Nicoletti, Tommaso, Bucci, Elisabetta, Fionda, Laura, Leonardi, Luca, Morino, Stefania, Tufano, Laura, Alfieri, Girolamo, Lauletta, Antonio, Merlonghi, Gioia, Perna, Alessia, Rossi, Salvatore, Ricci, Enzo, Alonso Perez, Jorge, Tartaglione, Tommaso, Petrucci, Antonio, Pennisi, Elena Maria, Salvetti, Marco, Cutter, Gary, Díaz‐Manera, Jordi, Silvestri, Gabriella, Antonini, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299773/
https://www.ncbi.nlm.nih.gov/pubmed/34753219
http://dx.doi.org/10.1111/ene.15174
_version_ 1784751053286146048
author Garibaldi, Matteo
Nicoletti, Tommaso
Bucci, Elisabetta
Fionda, Laura
Leonardi, Luca
Morino, Stefania
Tufano, Laura
Alfieri, Girolamo
Lauletta, Antonio
Merlonghi, Gioia
Perna, Alessia
Rossi, Salvatore
Ricci, Enzo
Alonso Perez, Jorge
Tartaglione, Tommaso
Petrucci, Antonio
Pennisi, Elena Maria
Salvetti, Marco
Cutter, Gary
Díaz‐Manera, Jordi
Silvestri, Gabriella
Antonini, Giovanni
author_facet Garibaldi, Matteo
Nicoletti, Tommaso
Bucci, Elisabetta
Fionda, Laura
Leonardi, Luca
Morino, Stefania
Tufano, Laura
Alfieri, Girolamo
Lauletta, Antonio
Merlonghi, Gioia
Perna, Alessia
Rossi, Salvatore
Ricci, Enzo
Alonso Perez, Jorge
Tartaglione, Tommaso
Petrucci, Antonio
Pennisi, Elena Maria
Salvetti, Marco
Cutter, Gary
Díaz‐Manera, Jordi
Silvestri, Gabriella
Antonini, Giovanni
author_sort Garibaldi, Matteo
collection PubMed
description BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. METHODS: One hundred and thirty‐four DM1 patients underwent a cross‐sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. RESULTS: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR‐positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. CONCLUSIONS: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials.
format Online
Article
Text
id pubmed-9299773
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92997732022-07-21 Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials Garibaldi, Matteo Nicoletti, Tommaso Bucci, Elisabetta Fionda, Laura Leonardi, Luca Morino, Stefania Tufano, Laura Alfieri, Girolamo Lauletta, Antonio Merlonghi, Gioia Perna, Alessia Rossi, Salvatore Ricci, Enzo Alonso Perez, Jorge Tartaglione, Tommaso Petrucci, Antonio Pennisi, Elena Maria Salvetti, Marco Cutter, Gary Díaz‐Manera, Jordi Silvestri, Gabriella Antonini, Giovanni Eur J Neurol Muscle and MNJ Disorders BACKGROUND: Only a few studies have reported muscle imaging data on small cohorts of patients with myotonic dystrophy type 1 (DM1). We aimed to investigate the muscle involvement in a large cohort of patients in order to refine the pattern of muscle involvement, to better understand the pathophysiological mechanisms of muscle weakness, and to identify potential imaging biomarkers for disease activity and severity. METHODS: One hundred and thirty‐four DM1 patients underwent a cross‐sectional muscle magnetic resonance imaging (MRI) study. Short tau inversion recovery (STIR) and T1 sequences in the lower and upper body were analyzed. Fat replacement, muscle atrophy and STIR positivity were evaluated using three different scales. Correlations between MRI scores, clinical features and genetic background were investigated. RESULTS: The most frequent pattern of muscle involvement in T1 consisted of fat replacement of the tongue, sternocleidomastoideus, paraspinalis, gluteus minimus, distal quadriceps and gastrocnemius medialis. Degree of fat replacement at MRI correlated with clinical severity and disease duration, but not with CTG expansion. Fat replacement was also detected in milder/asymptomatic patients. More than 80% of patients had STIR‐positive signals in muscles. Most DM1 patients also showed a variable degree of muscle atrophy regardless of MRI signs of fat replacement. A subset of patients (20%) showed a ‘marbled’ muscle appearance. CONCLUSIONS: Muscle MRI is a sensitive biomarker of disease severity alsofor the milder spectrum of disease. STIR hyperintensity seems to precede fat replacement in T1. Beyond fat replacement, STIR positivity, muscle atrophy and a ‘marbled’ appearance suggest further mechanisms of muscle wasting and weakness in DM1, representing additional outcome measures and therapeutic targets for forthcoming clinical trials. John Wiley and Sons Inc. 2021-12-06 2022-03 /pmc/articles/PMC9299773/ /pubmed/34753219 http://dx.doi.org/10.1111/ene.15174 Text en © 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Muscle and MNJ Disorders
Garibaldi, Matteo
Nicoletti, Tommaso
Bucci, Elisabetta
Fionda, Laura
Leonardi, Luca
Morino, Stefania
Tufano, Laura
Alfieri, Girolamo
Lauletta, Antonio
Merlonghi, Gioia
Perna, Alessia
Rossi, Salvatore
Ricci, Enzo
Alonso Perez, Jorge
Tartaglione, Tommaso
Petrucci, Antonio
Pennisi, Elena Maria
Salvetti, Marco
Cutter, Gary
Díaz‐Manera, Jordi
Silvestri, Gabriella
Antonini, Giovanni
Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title_full Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title_fullStr Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title_full_unstemmed Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title_short Muscle magnetic resonance imaging in myotonic dystrophy type 1 (DM1): Refining muscle involvement and implications for clinical trials
title_sort muscle magnetic resonance imaging in myotonic dystrophy type 1 (dm1): refining muscle involvement and implications for clinical trials
topic Muscle and MNJ Disorders
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299773/
https://www.ncbi.nlm.nih.gov/pubmed/34753219
http://dx.doi.org/10.1111/ene.15174
work_keys_str_mv AT garibaldimatteo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT nicolettitommaso musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT buccielisabetta musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT fiondalaura musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT leonardiluca musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT morinostefania musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT tufanolaura musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT alfierigirolamo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT laulettaantonio musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT merlonghigioia musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT pernaalessia musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT rossisalvatore musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT riccienzo musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT alonsoperezjorge musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT tartaglionetommaso musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT petrucciantonio musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT pennisielenamaria musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT salvettimarco musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT cuttergary musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT diazmanerajordi musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT silvestrigabriella musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials
AT antoninigiovanni musclemagneticresonanceimaginginmyotonicdystrophytype1dm1refiningmuscleinvolvementandimplicationsforclinicaltrials